Skip to main content

Expression of human telomerase reverse transcriptase splice variants is well correlated with low telomerase activity in osteosarcoma cell lines

Buy Article:

$42.00 + tax (Refund Policy)

The human telomerase reverse transcriptase (hTERT) gene is a catalytic subunit of telomerase that plays an important role in maintaining telomere length. Recently, post-transcriptional (alternative splicing) and epigenetic (promoter methylation) mechanisms affecting expression of the hTERT gene have been reported as negative regulators of telomerase activity (TA). To elucidate the significance of the telomere maintenance mechanism (TMM) in osteosarcoma (OS), we examined hTERT mRNA/protein expression and methylation status in 16 OS cell lines and compared them with TA. Five (31%) of 16 OS cell lines expressed both full-length and splice variants of hTERT mRNA/protein, and 3 (19%) exhibited only full-length hTERT mRNA/protein. No hTERT mRNA/protein expression was observed in 8 cell lines (50%). TA in OS cell lines exhibiting full-length hTERT mRNA/protein without any splice variants was higher than in cell lines expressing splice variants. The promoters of the 16 OS cell lines were relatively hypermethylated, but no inverse relationship between frequency of methyl-CpG sites and hTERT expression was observed. Treatment with a demethylating agent induced hTERT mRNA/protein in only one cell line. These results suggest that the epigenetic mechanism might contribute to the regulation of the hTERT gene in a small subset of OSs, and that alternative splicing might be involved in controlling the TA of OS cell lines, thereby contributing to their TMM.

Document Type: Research Article

Affiliations: Department of Pathology, Iwate Medical University School of Medicine, Morioka 020-8505, Japan

Publication date: 01 April 2005

More about this publication?
  • The International Journal of Oncology provides an international forum for the publication of the latest, cutting-edge research in the broad area of oncology and cancer treatment. The journal accepts original high quality works and reviews on all aspects of oncology research including carcinogenesis, metastasis, epidemiology, chemotherapy and viral oncology. Through fair and efficient peer review, the journal is dedicated to publishing top tier research in the field, offering authors rapid publication as well as high standards of copy-editing and production. The International Journal of Oncology is published on a monthly basis in both print and early online.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content